ストックスクリーナーアプリを入手
8.24
3.91%
0.31
アフターアワーズ：
8.24
前日終値:
$7.93
開ける：
$7.92
24時間の取引高:
256.66K
Relative Volume:
0.89
時価総額：
$264.49M
収益：
-
当期純損益:
$-62.31M
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-16.17%
1か月 パフォーマンス:
-4.85%
6か月 パフォーマンス:
-35.47%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.835
$8.38
1週間の範囲:
$7.54
$9.97
52週間の値動き範囲:
$7.54
$22.33
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
名前
Lexeo Therapeutics Inc
セクター
電話
(212) 547-9879
住所
345 PARK AVENUE SOUTH, NEW YORK
Lexeo Therapeutics Inc (LXEO) 最新ニュース
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat
Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum
Lexeo reports positive Alzheimer's drug trial results - Investing.com India
Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire
How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online
Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment - MarketWatch
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to - The Bakersfield Californian
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
(LXEO) Investment Analysis - Stock Traders Daily
Novo Holdings A S Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' (LXEO) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - The Manila Times
Lexeo Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference - StockTitan
R. Nolan Townsend - Crain's New York Business
(LXEO) Proactive Strategies - Stock Traders Daily
Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of Stock - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat
Long Term Trading Analysis for (LXEO) - Stock Traders Daily
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth - Investing.com India
Novo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth By Investing.com - Investing.com UK
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times
LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World
Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Quest Partners LLC Acquires 11,597 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! - SETE News
LXP Industrial Trust price target raised to $11 from $10 at Evercore ISI - TipRanks
Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 - The Dwinnex
Objective long/short (LXEO) Report - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus Price Target from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR
The Globe and Mail - The Globe and Mail
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Top investors say Lexeo Therapeutics Inc. (LXEO) ticks everything they need - SETE News
The Lexeo Therapeutics Inc. (LXEO) had a good session last reading, didn’t it? - US Post News
Short Interest in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Expands By 16.9% - MarketBeat
Trading (LXEO) With Integrated Risk Controls - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Average Price Target from Analysts - MarketBeat
Chardan Capital Comments on Lexeo Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:LXEO) - MarketBeat
Vanguard Group Inc. Grows Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Stifel maintains 'Buy' on Lexeo stock, confident amid trial progress By Investing.com - Investing.com Canada
Lexeo Therapeutics Inc (LXEO) 財務データ
収益
当期純利益
現金流量
EPS
5.11%
0.50%
大文字化:
|
ボリューム (24 時間):